Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
54.5M
-
Shares change
-
+495K
-
Total reported value, excl. options
-
$1.05B
-
Value change
-
+$14.5M
-
Put/Call ratio
-
0.11
-
Number of buys
-
55
-
Number of sells
-
-55
-
Price
-
$19.24
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q2 2022
138 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q2 2022.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.5M shares
of 86.6M outstanding shares and own 62.92% of the company stock.
Largest 10 shareholders include Avidity Partners Management LP (5.45M shares), BlackRock Inc. (3.8M shares), WELLINGTON MANAGEMENT GROUP LLP (3.21M shares), Frazier Life Sciences Management, L.P. (3.2M shares), VANGUARD GROUP INC (2.78M shares), Nantahala Capital Management, LLC (2.66M shares), Kynam Capital Management, LP (2.51M shares), STATE STREET CORP (2.44M shares), BVF INC/IL (2.36M shares), and ORBIMED ADVISORS LLC (2.32M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.